NDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ACTICLATE (doxycycline hyclate) by Molecular Devices is 12. First approved in 2014.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Acticlate is an oral tetracycline-class antimicrobial tablet containing doxycycline hyclate approved in 2014. It inhibits bacterial protein synthesis and is used to treat various bacterial infections across multiple therapeutic areas. The drug achieves peak plasma levels within 3 hours and maintains therapeutic concentrations for 24 hours.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial support but limited growth runway.
Mechanism of Action
12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours,…
Worked on ACTICLATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.